A new study shows patients with advanced non–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.
Underinsured patients use websites like GoFundMe to pay medical bills after being diagnosed with cancer, but many fundraising campaigns are unsuccessful.
The agency is now recommending prescribing certain medications to postmenopausal women at an increased risk for breast cancer in order to help prevent them from developing the disease.
A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.
A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
Researchers compared the demographics of patients in Oregon and Washington seeking medical aid in dying.
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival.
A new study surveyed 1,246 patients on whether they'd be willing to share electronic health records and biospecimens for research.
Researchers examined several studies of patients with Graves' Disease to see the prevalence of thyroid cancer in this population.